Zhijie Li, MD
I graduated from China Medical University, China in 1990 and received my PhD degree in 2000. I began to work for the Cell and Molecular Biology Section in 2003. My research project focuses on delineating the mechanism by which activation of the BDNF/TrkB signal transduction pathway protect Neuroblastoma cells from chemotherapy. I've identified that the PI3K/Akt signaling pathway is a key pathway. Small molecular inhibitors targeting TrkB and Akt are being tested to improve the sensitivity of Neuroblastoma cells. These preclinical models have identified a potential new strategy to improve the effects of chemotherapy in children with neuroblastoma tumors.